Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
vaccine administered reconstituted with non-approved diluent; vaccine administered reconstituted with non-approved diluent; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On 15-JAN-2025, the patient received the 1st dose of Menveo. On 15-JAN-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: vaccine administered reconstituted with non-approved diluent) and inappropriate dose of vaccine administered (Verbatim: vaccine administered reconstituted with non-approved diluent). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown. Additional Information: GSK Receipt Date: 15-JAN-2025 The pharmacy Intern reported that they administered Menveo (2-vial) but the powder was reconstituted with sterile water instead of the liquid component vial, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The reporter did not had any patient demographics, lot number or expiration date for the vaccine. This was the first dose of Menveo for this patient. The vaccine administration facility was the same as primary reporter.